| Genetic variants in C5 and poor response to eculizumab J Nishimura, M Yamamoto, S Hayashi, K Ohyashiki, K Ando, AL Brodsky, ... New England Journal of Medicine 370 (7), 632-639, 2014 | 424 | 2014 |
| ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy A Lazarowski, L Czornyj, F Lubienieki, E Girardi, S Vazquez, C D'Giano Epilepsia 48, 140-149, 2007 | 281 | 2007 |
| Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy A Lazarowski, G Sevlever, A Taratuto, M Massaro, A Rabinowicz Pediatric neurology 21 (4), 731-734, 1999 | 159 | 1999 |
| Intermittent hypoxia during sleep induces reactive gliosis and limited neuronal death in rats: implications for sleep apnea RX Aviles‐Reyes, MF Angelo, A Villarreal, H Rios, A Lazarowski, ... Journal of neurochemistry 112 (4), 854-869, 2010 | 127 | 2010 |
| Multidrug resistance proteins in tuberous sclerosis and refractory epilepsy A Lazarowski, F Lubieniecki, S Camarero, H Pomata, M Bartuluchi, ... Pediatric neurology 30 (2), 102-106, 2004 | 118 | 2004 |
| Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model A Lazarowski, AJ Ramos, H García-Rivello, A Brusco, E Girardi Cellular and molecular neurobiology 24, 77-85, 2004 | 107 | 2004 |
| Hypoxia, oxidative stress, and inflammation: three faces of neurodegenerative diseases A Merelli, M Repetto, A Lazarowski, J Auzmendi Journal of Alzheimer's Disease 82 (s1), S109-S126, 2021 | 101 | 2021 |
| Understanding the role of hypoxia inducible factor during neurodegeneration for new therapeutics opportunities A Merelli, JCG Rodríguez, J Folch, MR Regueiro, A Camins, A Lazarowski Current Neuropharmacology 16 (10), 1484-1498, 2018 | 94 | 2018 |
| Masitinib for the treatment of mild to moderate Alzheimer’s disease J Folch, D Petrov, M Ettcheto, I Pedros, S Abad, C Beas-Zarate, ... Expert review of neurotherapeutics 15 (6), 587-596, 2015 | 82 | 2015 |
| P-glycoprotein—a clinical target in drug-refractory epilepsy? RW Robey, A Lazarowski, SE Bates Molecular pharmacology 73 (5), 1343-1346, 2008 | 77 | 2008 |
| Neuronal and Glial Alterations Due to Focal Cortical Hypoxia Induced by Direct Cobalt Chloride (CoCl2) Brain Injection L Caltana, A Merelli, A Lazarowski, A Brusco Neurotoxicity research 15, 348-358, 2009 | 76 | 2009 |
| Potential role of multidrug resistant proteins in refractory epilepsy and antiepileptic drugs interactions A Lazarowski, L Czornyj Walter de Gruyter 26 (1), 21-26, 2011 | 75 | 2011 |
| Neuronal MDR-1 gene expression and persistent low levels of anticonvulsants in a child with refractory epilepsy A Lazarowski, M Massaro, A Schteinschnaider, S Intruvini, G Sevlever, ... Therapeutic drug monitoring 26 (1), 44-46, 2004 | 73 | 2004 |
| Neuronal mdr-1 gene expression after experimental focal hypoxia: a new obstacle for neuroprotection? A Lazarowski, L Caltana, A Merelli, MD Rubio, AJ Ramos, A Brusco Journal of the neurological sciences 258 (1-2), 84-92, 2007 | 71 | 2007 |
| Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model C Höcht, A Lazarowski, NN Gonzalez, J Auzmendi, JAW Opezzo, ... Neuroscience letters 413 (2), 168-172, 2007 | 68 | 2007 |
| Erythropoietin: a neuroprotective agent in cerebral hypoxia, neurodegeneration, and epilepsy A Merelli, L Czornyj, A Lazarowski Current pharmaceutical design 19 (38), 6791-6801, 2013 | 52 | 2013 |
| Erythropoietin as a new therapeutic opportunity in brain inflammation and neurodegenerative diseases A Merelli, L Czornyj, A Lazarowski International Journal of Neuroscience 125 (11), 793-797, 2015 | 49 | 2015 |
| Cerebral arteritis following methylphenidate use A Schteinschnaider, L Lemme Plaghos, S Garbugino, D Riveros, ... Journal of Child Neurology 15 (4), 265-267, 2000 | 48 | 2000 |
| Cardiomyocytes of chronically ischemic pig hearts express the MDR-1 gene-encoded P-glycoprotein AJ Lazarowski, HJG Rivello, GLV Janavel, LA Cuniberti, PMC Meckert, ... Journal of Histochemistry & Cytochemistry 53 (7), 845-850, 2005 | 46 | 2005 |
| Mavoglurant as a treatment for Parkinson’s disease D Petrov, I Pedros, ML de Lemos, M Pallas, AM Canudas, A Lazarowski, ... Expert opinion on investigational drugs 23 (8), 1165-1179, 2014 | 40 | 2014 |
